Do guidelines for severe mental illness promote physical health and well-being?

Journal of Psychopharmacology

Volumn 19, Issue 6 SUPPL., 2005, Pages 102-109

  Citrome, Leslie ^a,b   Yeomans, David ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Bipolar disorder; Guidelines; Holistic; Physical health; Schizophrenia; Severe mental illnesses (SMI); Treatment

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; EMOTION; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; FITNESS; GLUCOSE BLOOD LEVEL; HEALTH CARE NEED; HEALTH PROMOTION; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPONATREMIA; LETHARGY; LIFESTYLE; LIPID BLOOD LEVEL; MENTAL DISEASE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; METABOLIC DISORDER; METABOLISM; NEUROLOGIC DISEASE; OBESITY; PATIENT MONITORING; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL CARE; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; UNITED KINGDOM; UNITED STATES; WEIGHT GAIN; WELLBEING;

BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; GUIDELINE ADHERENCE; HEALTH PROMOTION; HOLISTIC HEALTH; HUMANS; LIFE STYLE; MENTAL HEALTH; NATIONAL HEALTH PROGRAMS; PHYSICAL FITNESS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK REDUCTION BEHAVIOR; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 33746123940     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881105059505     Document Type: Review

References (30)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596-601
2. Bazire S (2003) Psychotropic Drug Directory 2003/2004. Fivepin Publishing Limited, Salisbury
3. Buckley P F, Miller D D, Singer B, Arena J, Stirewalt E M (in press) Clinicians' appreciation of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research
4. Casey D E, Haupt D W, Newcomer J W, Henderson D C, Sernyak M J, Davidson M, Lindenmayer J P, Manoukian S V, Banerji M A, Lebovitz H E, Hennekens C H (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl 7): 4-18
5. Citrome L (1998) Practice protocols, parameters, pathways, and guidelines: a review. Adm Policy Ment Health 25: 257-269
6. Citrome L, Volavka J (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 27: 2087-2088
7. Citrome L, Volavka J (2005) Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. J Clin Psychiatry 66: 1073-1074
8. Department of Health (2004a) Public Health White Paper. Choosing Health: Making Healthier Choices Easier. Chapter 6, section 43. Available at: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ID=4094550&chk=aN5Cor
9. Department of Health (2004b). PRODIGY guidance - schizophrenia. Available at: www.prodigy.nhs.uk/guidance.asp?gt=Schizophrenia
10. Dinan T G (ed.) (2004) Schizophrenia and diabetes 2003: an expert consensus meeting. Br J Psychiatry 184 (suppl 47): s53-s54
11. Goodwin G M for the Consensus Group of the British Association for Psychopharmacology (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17: 149-173
12. Lehman A F, Lieberman J A, Dixon L B, McGlashan T H, Miller A L, Perkins D O, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry 161 (2 Suppl): 1-56
13. McCreadie R, MacDonald E, Blackock C, Tilak-Singh D, Wiles D, Halliday J, Paterson J (1998) Dietary intake of schizophrenic patients in Nithsdale, Scotland: Case-Control study. BMJ 317: 784-785
14. McCreadie R G, Scottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183: 534-539
15. Marder S R, Essock S M, Miller A L, Buchanan R W, Davis J M, Kane J M, Lieberman J, Schooler N R (2002) The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28: 5-16
16. Marder S R, Essock S M, Miller A L, Buchanan R W, Casey D E, Davis J M, Kane J M, Lieberman J A, Schooler N R, Covell N, Stroup S, Weissman E M, Wirshing D A, Hall C S, Pogach L, Pi-Sunyer X, Bigger J T Jr, Friedman A, Kleinberg D, Yevich S J, Davis B, Shon S (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349
17. National Institute for Clinical Excellence (NICE) (2002a) Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline 1, London. Available at: http://www.nice.org.uk
18. National Institute for Clinical Excellence (NICE) (2002b) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No. 43, London. Available at: http://www.nice.org.uk
19. National Institute for Clinical Excellence (NICE) (2003) Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar disorder. Technology Appraisal 66, London. Available at: http://www.nice.org.uk
20. Newcomer J W, Nasrallah H A, Loebel A D (2004) The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24 (Suppl 1): S1-6
21. Ryan M, Collins P, Thakore J (2003) Impaired fasting glucose tolerance in first episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160: 284-289
22. Slovenko R (2000) Update on legal issues associated with tardive dyskinesia. J Clin Psychiatry 61(Suppl 4): 45-57
23. Stroup T S (2004) Antipsychotic drug treatment of schizophrenia: update on the CATIE trial. In: NCDEU Abstracts from the 44th Annual Meeting, June 1-4, 2004, Phoenix, Arizona. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Bethesda, MD, p. 27
24. Susce M T, Villanueva N, Diaz F J, de Leon J (2005) Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66: 167-173
25. Tandon R (1998) Antipsychotic agents. In Quitkin F M, Adams D C, Bowden C L, Heyer E S, Rifkin A, Sellers E M, Tandon R, Taylor B P (eds), Current Psychotherapeutic Drugs, 2nd edn. Current Medicine, Philadelphia, PA
26. Taylor D, Paton C, Kerwin R (2005) The Maudsley 2005-2006 Prescribing Guidelines, 8th edn. Taylor & Francis, London
27. Thompson C (1994) The use of high-dose antipsychotic medication. Br J Psychiatry 164: 448-458
28. TNS Healthcare (2005a) Omnibus survey conducted amongst 209 UK General Practitioners. Published in: Running on Empty: Building Momentum for Complete Well-Being in Severe Mental Illness. Available at: http://www.rethink.org/ news+campaigns/press_releases/running-on-empty.htm
29. TNS Healthcare (2005b) SPOTLIGHT research programme amongst individuals with SMI. Published in: Running on Empty: Building Momentum for Complete Well-Being in Severe Mental Illness. Available at: http://www.rethink.org/ news+campaigns/press_releases/running-on-empty.htm
30. Wallace B, Tennant C (1998) Nutrition and obesity in the chronically mentally ill. Aust N Z J Psychiatry 32: 82-85